Biomarkers in asthmatic patients: Has their time come to direct treatment?
详细信息 查看全文
- 作者：Alalia Berry ; MD ; William W. Busse ; MD ; wwb@medicine.wisc.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Asthma ; biomarkers ; eosinophil ; IgE ; periostin ; nitric oxide
- 刊名：Journal of Allergy and Clinical Immunology
- 出版年：2016
- 出版时间：May 2016
- 年：2016
- 卷：137
- 期：5
- 页码：1317-1324
- 全文大小：1080 K
文摘
Asthma is a heterogeneous disease with multiple phenotypes that have variable risk factors and responses to therapeutics. Mild-to-moderate asthma often responds to traditional medications, whereas severe disease can be refractory to inhaled corticosteroids, long-acting β-agonists, and leukotriene receptor antagonists. There is robust research into the variable phenotypes of asthma. Biomarkers help define the specific pathophysiology of different asthma phenotypes and identify potential therapeutic targets. The following review will discuss the current use of biomarkers for the diagnosis of asthma, triaging the severity of a patient's disease, and the potential efficacy of treatments. This information can be used to define certain patient populations that are more likely to respond to inhaled corticosteroids or biologics. As knowledge of patient phenotypes and endotypes and biological agents to target specific classes of asthma emerge, the ability to provide personalized care to asthmatic patients will follow.